News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
616,732 Results
Type
Article (47515)
Company Profile (245)
Press Release (568972)
Section
Business (177300)
Career Advice (2583)
Deals (32660)
Drug Delivery (117)
Drug Development (78996)
Employer Resources (162)
FDA (16260)
Job Trends (13641)
News (313974)
Policy (32488)
Tag
Academia (2412)
Alliances (44757)
Alzheimer's disease (1338)
Approvals (16195)
Artificial intelligence (152)
Bankruptcy (318)
Best Places to Work (10159)
Biotechnology (131)
Breast cancer (188)
Cancer (1386)
Cardiovascular disease (113)
Career advice (2150)
Cell therapy (296)
Clinical research (63240)
Collaboration (467)
Compensation (268)
COVID-19 (2625)
C-suite (109)
Data (1347)
Diabetes (183)
Diagnostics (5480)
Drug pricing (106)
Earnings (68883)
Employer resources (147)
Events (93024)
Executive appointments (382)
FDA (16954)
Funding (387)
Gene therapy (209)
GLP-1 (695)
Government (3965)
Healthcare (15941)
Infectious disease (2722)
Inflammatory bowel disease (115)
Interviews (472)
IPO (15216)
Job creations (3881)
Job search strategy (1810)
Layoffs (469)
Legal (7856)
Lung cancer (208)
Manufacturing (223)
Medical device (11451)
Medtech (11455)
Mergers & acquisitions (17616)
Metabolic disorders (524)
Neuroscience (1685)
NextGen Class of 2024 (5519)
Non-profit (3429)
Northern California (1636)
Obesity (304)
Opinion (237)
Parkinson's disease (102)
Patents (125)
People (51792)
Phase I (19449)
Phase II (27454)
Phase III (21434)
Pipeline (523)
Postmarket research (2624)
Preclinical (7915)
Radiopharmaceuticals (238)
Rare diseases (277)
Real estate (5396)
Regulatory (22208)
Research institute (2227)
Resumes & cover letters (429)
Southern California (1386)
Startups (3338)
United States (14386)
Vaccines (644)
Weight loss (239)
Date
Today (15)
Last 7 days (458)
Last 30 days (2327)
Last 365 days (33986)
2024 (33866)
2023 (37974)
2022 (48616)
2021 (52387)
2020 (49764)
2019 (40586)
2018 (30990)
2017 (31325)
2016 (30100)
2015 (33767)
2014 (27445)
2013 (23121)
2012 (24762)
2011 (25359)
2010 (23333)
Location
Africa (787)
Arizona (158)
Asia (38494)
Australia (6198)
California (3623)
Canada (1290)
China (285)
Colorado (169)
Connecticut (190)
Europe (86988)
Florida (517)
Georgia (119)
Illinois (350)
Indiana (195)
Maryland (621)
Massachusetts (2887)
Michigan (143)
Minnesota (258)
New Jersey (1070)
New York (1015)
North Carolina (739)
Northern California (1636)
Ohio (123)
Pennsylvania (856)
South America (1164)
Southern California (1386)
Texas (520)
Washington State (383)
616,732 Results for "novartis pharma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphyoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
Drug pricing
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.
October 21, 2024
·
2 min read
·
Tristan Manalac
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
Huntington’s disease
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
December 2, 2024
·
2 min read
·
Tristan Manalac
1 of 61,674
Next
